azd4205 + osimertinib

**AZD4205 + osimertinib** is a combination investigational regimen being studied for cancer treatment, primarily in non-small cell lung carcinoma (NSCLC) and peripheral T-cell lymphoma. AZD4205 is an oral, ATP-competitive, selective Janus kinase 1 (JAK1) inhibitor, demonstrating high selectivity for JAK1 and favorable pharmacokinetic properties that result in higher drug concentrations in the gastrointestinal tract relative to plasma[2][5]. Its mechanism is inhibition of the JAK-STAT pathway, reducing cytokine-driven signaling. Osimertinib is an approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), targeting activating EGFR mutations as well as T790M resistance mutations, operating via covalent inhibition of mutant EGFR kinase and blocking downstream cell proliferation pathways. The combination aims to overcome acquired resistance mechanisms in EGFR-mutated NSCLC where JAK-STAT signaling may contribute to tumor progression alongside EGFR activation[5]. Dizal Pharmaceuticals is developing AZD4205[1], while AstraZeneca develops osimertinib (Tagrisso)[5].

Brand names

Tagrisso

Other names

AZD4205 + Tagrisso